The research on important prognostic factors after LT has shown that, in addition to the size and number of tumors, the presence of vascular invasion and grade of histological differentiation are ...

Please provide your email address to receive an email when new articles are posted on . Researchers have proposed a machine-learning algorithm for personalized treatment selection in patients with ...

An international randomized controlled trial, advised by a steering committee co-led by a senior clinician-scientist from the National Cancer Centre Singapore and Duke-NUS Medical School, Singapore, ...

Molecular profile of hepatocellular carcinoma (HCC) in older (OA) versus younger adults (YA) receiving tyrosine kinase inhibitors: Does age matter? This is an ASCO Meeting Abstract from the 2025 ASCO ...

ORLANDO, Florida — Patients with hepatocellular carcinoma (HCC) who undergo surgery or thermal ablation with curative intent are at high risk for recurrence, but currently, no adjuvant therapy ...

A team of clinician-scientists and researchers from the National Cancer Centre Singapore (NCCS), Agency for Science, Technology and Research (A*STAR), the Harry Perkins Institute of Medical Research ...

Artificial intelligence (AI) models have potential to help clinicians assess risk in patients with hepatocellular carcinoma (HCC) to inform disease management, a new study found. In HCC that is not ...

Hepatocellular carcinoma (HCC), the most prevalent form of primary liver cancer, remains a leading cause of cancer-related mortality worldwide. Although radiofrequency ablation (RFA) is the first-line ...

Serum alpha-fetoprotein (AFP) is the current standard of care and only approved biomarker for hepatocellular carcinoma (HCC), used for diagnosis, outcome prediction, long-term follow-up, and treatment ...

Phase II trial of ixabepilone (IXA) plus cetuximab (C) as first-line therapy for advanced pancreatic carcinoma (PC). Background: Although current selection criteria have led to a significant decrease ...